<DOC>
	<DOCNO>NCT00019838</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop cancer cell divide stop grow die . Combining UCN-01 chemotherapy may kill tumor cell . PURPOSE : This phase I trial study side effect best dose fludarabine give UCN-01 treating patient recurrent refractory low-grade lymphoma leukemia .</brief_summary>
	<brief_title>UCN-01 Fludarabine Treating Patients With Recurrent Refractory Lymphoma Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerated dose toxic effect fludarabine administer UCN-01 patient recurrent refractory low-grade indolent lymphoid malignancy . - Determine , preliminarily , activity treatment regimen patient . - Assess pharmacokinetics treatment regimen patient . OUTLINE : This dose-escalation study fludarabine . Patients receive UCN-01 IV 72 hour day 1-3 alone course 1 36 hour day 1-2 course 2-7 . Patients also receive fludarabine IV 30 minute begin day 1 continue 5 day course 2-7 . Courses repeat every 28 day absence unacceptable toxicity disease progression . Cohorts 3-6 patient receive escalate dos fludarabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Patients follow every 2 month 6 month , every 3 month 1 year , every 6 month thereafter . PROJECTED ACCRUAL : Approximately 20 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>7-hydroxystaurosporine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Staurosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm recurrent refractory lowgrade indolent lymphoid malignancy require systemic therapy , include follow : Grade I II follicular small cleave cell lymphoma Small lymphocytic lymphoma/leukemia subtypes ( chronic lymphocytic leukemia ) Mantle cell lymphoma Waldenstrom 's macroglobulinemia Lymphoplasmacytoid Marginal zone ( nodal , extranodal , splenic subtypes ) Hairy cell leukemia Transformed indolent subtypes allow provided 1 follow criterion meet : Previously treat doxorubicincontaining regimen No rapidly progress disease threaten vital function Measurable disease No active leptomeningeal parenchymal CNS lymphoma NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,000/mm^3 Platelet count least 50,000/mm^3 No active Coomb'spositive hemolytic anemia Hepatic : Total bilirubin le 2.0 mg/dL ( unless elevation due Gilbert 's disease direct bilirubin normal ) Renal : Creatinine le 1.5 mg/dL OR Creatinine clearance great 60 mL/min Cardiovascular : No angina No congestive heart failure No myocardial infarction within past 6 month Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No insulindependent diabetes mellitus PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics More 3 week since prior systemic chemotherapy recover Endocrine therapy : More 3 week since prior systemic steroid therapy recover Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2005</verification_date>
	<keyword>Waldenstr√∂m macroglobulinemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>